MoHAP, Janssen & Axios expand the “Hand in Hand” initiative

MoHAP, Janssen & Axios expand the “Hand in Hand” initiative

The UAE Ministry of Health and Prevention (MoHAP), Janssen Pharmaceutical Companies of Johnson & Johnson, and the Dubai-based global healthcare consulting firm Axios, have jointly signed an appendix to the Memorandum of Understanding (MoU) to expand the scope of the “Hand in Hand” initiative.

The “Hand in Hand” Initiative aims to provide affordable medicines to uninsured and low-income expat patients or those whose insurance is not covering the cost of treatment of diseases such as pulmonary arterial hypertension, multiple myeloma, active ulcerative colitis, and psoriatic arthritis.

The MoU was first signed by the end of 2018, and about 712 eligible patients benefited from it. In April 2019, an extension of the program was signed to provide new medication to patients with the aforementioned conditions.

The MoU was signed by Dr. Amin Hussein Al-Amiri, Assistant Undersecretary for the Health Regulation Sector, MoHAP, Ms. Jimmy Faris, Managing Director, the Janssen Pharmaceutical Companies of Johnson & Johnson, and Mr. Anas Al-Safarini, Axios International Senior Director, MENA.

The agreement which is part of the trio’s commitment to improving access to innovative drugs, was signed at the US Pavilion, Expo 2020 Dubai, in the presence of the US Consul General Ms. Meghan Gregonis and the accompanying delegation along with